【参】六角形画像()
H1

Company Profile

コンテンツ
Our Philosophy

Our Philosophy

Biotech Striving for value creation
For comprehensive healthcare system for children as well as families and society

Access

Access

Company name Kidswell Bio Corporation
Head Office Kanayama Bldg. 3F, 1-2-12, Shinkawa, Chuo-ku, Tokyo, 104-0033, Japan
Tel: +81-3-6222-9547 Fax: +81-3-6222-9548
Established March 1, 2001
Capital 1,032,179,318yen(As of March 31, 2021)
Executives Masaharu Tani, President & CEO
Norikazu Eiki, Board of Director
Aya Chiba, Board of Director
Osamu Sugawara, Audit & Supervisory Board Member
Masato Mori, Audit & Supervisory Board Member
Hiroshi Shinagawa, Audit & Supervisory Board Member
Masayuki Kawakami, Chief Technology Officer
Shinya Kurebayashi, Chief Business Officer
Yasuo Sakae, Chief Financial Officer

Access

Head Office

Address

Kanayama Bldg. 3F, 1-2-12, Shinkawa, Chuo-ku,
Tokyo, 104-0033, Japan

Tel: +81-3-6222-9547 Fax: +81-3-6222-9548

Public transportation

2-minute walk from Kayabacho Station (Tokyo Metro Hibiya Line)
2-minute walk from Kayabacho Station (Tokyo Metro Tozai Line)

Organization

Organization

History

History

  • 2001
  • March
  • Gene Techno Science was established in Kita-ku, Sapporo with capital of ¥10 million. One goal was to develop of diagnostic and treatment drugs associated with research at the Hokkaido University Institute for Genetic Medicine involving functions of immune proteins, and performing outsourced tasks for pharmaceuticals development.
  • September
  • September – Formed the Bio Infomatics Sapporo Consortium with Hokudo Co., Ltd., New Drug Development Research Institute Co., Ltd., Japan Laser Electronics Co., Ltd., and Immuno-Biological Laboratories Co., Ltd.
  • 2002
  • June
  • Established a laboratory at the National Institute of Advanced Industrial Science and Technology Hokkaido (Toyohira-ku, Sapporo) to strengthen new biologics R&D; started considering the development of biosimilar business.
  • July
  • Project to create a model for ataxia caused by cerebellar dysfunction received a creative technology R&D subsidy from the Ministry of Economy, Trade and Industry.
  • July
  • With Hokudo, New Drug Development Research Institute and Immuno-Biological Laboratories, received a subsidy from the Hokkaido Small Business Support Center for a project to search for new genes for disease models used for drug discovery and development.
  • August
  • Certified as a start-up company (Progress creation category) by the National Institute of Advanced Industrial Science and Technology (AIST).
  • 2003
  • November
  • Moved the head office to the research center.
  • 2007
  • June
  • In the new biologics business, out-licensed anti alpha-9 integrin antibodies to Kaken Pharmaceutical Co., Ltd.
  • October
  • Signed joint development agreement for filgrastim biosimilar with Fuji Pharma Co., Ltd.
  • 2008
  • January
  • In the biosimilar business, signed a license agreement with Dong-A Pharmaceuticals Co., Ltd. to receive filgrastim cell line and basic production technology.
  • April
  • Moved the head office to Chuo-ku, Sapporo.
  • May
  • Moved the research center to the Hokkaido University Institute for Genetic Medicine (Kita-ku, Sapporo).
  • June
  • Established the Tokyo Office (Chuo-ku, Tokyo).
  • 2012
  • November
  • Fuji Pharma Co., Ltd. and MOCHIDA PHARMACEUTICAL CO., LTD. received approval for manufacturing and sale in Japan of filgrastim biosimilars (launched in May 2013), which were co-developed by Gene Techno Science and Fuji Pharma Co., Ltd.
  • November
  • Listed on the Tokyo Stock Exchange Mothers Market.
  • 2013
  • August
  • Established a capital and business alliance in the biosimilar business with ITOCHU CHEMICAL FRONTIER Corporation.
  • September
  • Moved the research center to the Center for Promotion of Platform for Research on Biofunctional Molecules at the Hokkaido University Creative Research Institution.
  • 2014
  • January
  • Signed an agreement with SANWA KAGAKU KENKYUSHO CO., LTD. for the joint development of darbepoetin alfa biosimilar.
  • June
  • Signed an agreement with GeneDesign Inc. for a nucleic acid joint business to commercialize nucleic acid drug development platforms.
  • November
  • Signed a capital and business alliance with ORTHOREBIRTH CO. LTD. for synthetic bone R&D
  • 2015
  • July
  • Dydo DRINKO, Inc. purchased Gene Techno Science stock as a first step for joint activities involving health care.
  • August
  • Signed business alliance memorandum with MOCHIDA PHARMACEUTICAL CO., LTD. for the joint development and sale of oncology biosimilars.
  • November
  • Signed capital and business alliance memorandum with Senju Pharmaceutical Co., Ltd. for the joint development and sale of ophthalmology biosimilars.
  • November
  • Moved the Tokyo Office to the current location in Chuo-ku, Tokyo.